<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR31">
 <label>31.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ishigami</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Fujiwara</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Fukushima</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Nashimoto</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Yabusaki</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Imano</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Imamoto</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Kodera</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Uenosono</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Amagai</surname>
    <given-names>K</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase III trial comparing Intraperitoneal and intravenous paclitaxel plus S-1 versus Cisplatin plus S-1 in patients with gastric Cancer with peritoneal metastasis: PHOENIX-GC trial</article-title>
  <source>J Clin Oncol</source>
  <year>2018</year>
  <volume>36</volume>
  <issue>19</issue>
  <fpage>1922</fpage>
  <lpage>1929</lpage>
  <pub-id pub-id-type="doi">10.1200/JCO.2018.77.8613</pub-id>
  <pub-id pub-id-type="pmid">29746229</pub-id>
 </element-citation>
</ref>
